Special Diabetes Program: Funding Opportunities
Below are current funding opportunities supported by the Special Diabetes Program. For other NIH funding opportunities, please see the NIH Guide for Grants and Contracts.
View archived research funding opportunities.
| Posted Date | Title | Open Date (Earliest Submission Date) | Application Due Date | Full Announcement |
|---|---|---|---|---|
| 8/31/2021 | National Program for the Career Development of Physician Scientists in Diabetes Research (Diabetes - Docs) (K12 Clinical Trial Optional) | October 18, 2021 | November 18, 2021 | RFA-DK-21-019 |
| 8/12/2021 | High-Resolution Exploration of the Human Islet Tissue Environment [HIRN Human Pancreas Analysis Consortium (HPAC)] (U01- Clinical Trial Not Allowed) | February 3, 2022 | March 3, 2022 | RFA-DK-21-017 |
| 8/4/2021 | Cardiovascular Biorepository for Type 1 Diabetes (U24 Clinical Trial Not Allowed) | September 20, 2021 | October 20, 2021 | RFA-DK-21-010 |
| 7/28/2021 | Pilot and Feasibility Studies to Improve Technology Adoption and Reduce Health Disparities in Type 1 Diabetes Mellitus (R01 Clinical Trial Required) | February 3, 2022 | March 3, 2022 | RFA-DK-21-018 |
| 7/14/2021 | Continuation of The Collaborative Islet Transplantation Registry (U01 Clinical Trial Not Allowed) | September 20, 2021 | October 20, 2021 | RFA-DK-21-013 |
| 6/25/2021 | Support for Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed) | January 17, 2022 | February 17, 2022 and October 7, 2022 | RFA-DK-21-021 |
| 6/3/2021 | Characterization of Islet-derived Extracellular Vesicles for Improved Detection, Monitoring, Classification, and Treatment of Type 1 Diabetes (R01 Clinical Trial Not Allowed) | October 3, 2021 | November 3, 2021 | RFA-DK-21-016 |
| 5/19/2021 | Support for Small Business Innovation Research (SBIR) Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed) | February 9, 2022 | March 9, 2022 and October 7, 2022 | RFA-DK-21-012 |
| 5/7/2021 | Standardization of C-peptide and HbA1C Measurements Program (U01 Clinical Trial Not Allowed) | September 20, 2021 | October 20, 2021 | RFA-DK-21-007 |
| 5/6/2021 | Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed) | February 9, 2022 | March 9 and October 7, 2022 | RFA-DK-21-011 |
| 4/6/2021 | Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01 Clinical Trial Optional) | September 20, 2021 | October 20, 2021 | RFA-DK-21-006 |
| 4/5/2021 | Limited Competition: Revision to the Longitudinal Monitoring of Pancreas Architecture in the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional) | July 17, 2021 | August 17, 2021 | RFA-DK-21-501 |
| 3/17/2021 | The Autoantigens and Neoantigens Function in the Etiology and Pathophysiology of Type 1 Diabetes (R01 Clinical Trial Optional) | May 22, 2021 | June 22, 2021 and March 9, 2022 | RFA-DK-21-004 |
| 1/13/2021 | Biomarkers for Diabetic Foot Ulcers through the Diabetic Foot Consortium (R61/R33 Clinical Trial Not Allowed) | March 22, 2021 | April 22 and November 3, 2021 | RFA-DK-21-001 |
| 1/6/2021 | Understanding and Reducing Cardiovascular Disease in Type 1 Diabetes Mellitus (R01-Clinical Trial Optional) | February 15, 2021 | March 15 and October 15, 2021 | RFA-HL-21-014 |
| 1/3/2014 | Diabetic Complications Consortium Preclinical Testing Program | Ongoing | Not Applicable | DCC-PTP Website |